We identified seven putative splice variants of the human IG20 gene. Four variants namely, IG20, MADD, IG20-SV2 and DENN-SV are expressed in human tissues. While DENN-SV is constitutively expressed in all tissues, expression of IG20 appears to be regulated. Interestingly, overexpression of DENN-SV enhanced cell replication and resistance to treatments with TNFa, vinblastine, etoposide and c-radiation. In contrast, IG20 expression suppressed cell replication and increased susceptibility to the above treatments. Moreover, cells that were resistant and susceptible to TNFa-induced apoptosis exclusively expressed endogenous DENN-SV and IG20, respectively. When PA-1 ovarian cancer cells that are devoid of endogenous IG20 variant, but express higher levels of DENN-SV, were transfected with IG20, they showed reduced cell proliferation and increased susceptibility to apoptosis induced by TNFa, TRAIL and c-radiation. This indicated that overexpression of IG20 can override endogenous DENN-SV function. CrmA reversed the effects of IG20, but not DENN-SV. In contrast, dominant-negative-I-kappa B reversed the effects of DENN-SV, but not IG20, and showed that DENN-SV most likely exerted its effects through NFjB activation. Together, our data show that IG20 gene can play a novel and significant role in regulating cell proliferation, survival and death through alternative mRNA splicing.
Introduction
Eukaryotes have evolved the process of alternative mRNA splicing for generating multiple protein isoforms from the same gene (Herbert and Rich, 1999; Smith and Valcarcel, 2000) . It is a highly regulated process that ensures removal of nucleotides at specific locations without disrupting the open reading frame (Sharp, 1994; Jiang and Wu, 1999) . Alternative mRNA splicing could remove either a whole exon or part of an exon resulting in different transcripts capable of encoding related, but distinct, proteins (Breitbart et al., 1987) . Since the completion of the human genome sequencing, it has become apparent that the biological complexity seen in humans, relative to other lower species, is most likely due to a higher degree of alternative splicing in human genes (Goldstrohm et al., 2001) . Earlier results demonstrated that IG20 is one such gene that undergoes alternative mRNA splicing resulting in the production of multiple proteins (Chow and Lee, 1996; Chow et al., 1998; Al-Zoubi and Efimova et al., 2001) .
Recently, we showed that IG20 and IG20-SV2, and the previously reported KIAA0358 (Nagase et al., 1997) , MADD (Schievella et al., 1997) and DENN-SV (Chow and Lee, 1996) are splice variants of the IG20 gene, which is localized to chromosome 11p11 and consists of 36 exons (Al-Zoubi and Efimova et al., 2001) . Differences among the above variants are due to alternative splicing of exons 13L, 16, 21, 26 and 34 . Cell transfection studies showed that IG20 and DENN-SV conferred susceptibility and resistance, respectively, to TNFa-induced apoptosis, whereas MADD expression had no discernible effect (Al-Zoubi and Efimova et al., 2001) . All three variants interacted with tumor necrosis factor type 1 (TNFR1) and enhanced activation of the extracellular-regulated kinase (ERK), but only IG20 enhanced activation of caspases 8 and 3. Further, we showed that IG20-mediated, TNFa-induced apoptosis could be abrogated by the caspase inhibitor, CrmA (AlZoubi and Efimova et al., 2001) . These results suggested that enhancement of apoptosis by IG20 is mainly dependent on activation of caspases 8 and 3. However, the mechanism by which DENN-SV confers resistance to apoptosis is yet to be determined. In addition, several studies have implicated a role for IG20 splice variants in apoptosis and cell proliferation (Murakami-Mori et al., 1999; Al-Zoubi and Efimova et al., 2001; Lim and Chow, 2002) . However, to date, no systematic study has been conducted to determine which variants are naturally expressed in human tumors and whether they might influence tumor cell growth and/or susceptibility to various treatments leading to induced cell death.
In this study, we show that four IG20 splice variants are expressed in various human tissues. More interestingly, we show that DENN-SV is constitutively expressed in all human tissues with higher expression in tumors. Transfecting cells with DENN-SV caused enhanced proliferation and resistance to apoptosis induced by commonly used cancer treatments, whereas transfecting them with IG20 showed reduced cell proliferation and increased susceptibility. Additionally, while CrmA reversed TNFa-induced apoptosis in cells expressing IG20, dominant-negative IkBa, which inhibits NFkB activation, reversed DENN-SV-mediated resistance to apoptosis. Transfection of cDNA encoding IG20 variant into cells of an ovarian cancer cell line that do not naturally express it, led to a significant decrease in their proliferation and a marked increase in susceptibility to various apoptosis-inducing agents. Collectively, these studies show that IG20 expression can be used to render cells susceptible to apoptosis with potential implications for cancer therapy.
Results

Identification of IG20 splice variants
Analyses of cDNA sequences (Figure 1) showed that all seven variants of IG20 identified to date arise from alternative splicing of exons 13L, 16, 21, 26 and 34. The full-length cDNA of IG20 (IG20-FL) (accession number AF440100) is 5995 base pairs (bps) long, consists of all 36 exons and represents the longest variant. Splicing of exon 34 alone generates KIAA0358 (accession number AB002356) that consists of 5942 bps. Splicing of exons 21 and 26, and splicing of exons 16, 21 and 26 generate 5878 bps long IG20 (accession number AF440101) and 6002 bps long MADD (accession number U77352), respectively. MADD is also known as DENN (accession number U44953) that is 5844 bps long . Splicing of exons  13L, 21 and 26, and 13L, 16, 21 and 26 generate  5749 bps long IG20-SV2 (accession number AF440102) and 5689 bps long IG20-SV3 (accession number AF440103) (earlier referred to as DENN-SV). Finally, splicing of all five exons (13L, 16, 21, 26 and 34) generates IG20-SV4 (accession number AF440434), which is the shortest variant and consists of 5619 bps. Sequencing of cDNAs from several tissues and cell lines confirmed that bands of the same size have identical sequences. Differences in nucleotide sequences among various variants are not limited to splicing of the above exons, and include nucleotide sequences upstream of the ATG start codon and downstream of the stop codon as reported by us and others. It is not clear as to why these differences exist and what their implications are, and further studies are needed to resolve this fully.
Only IG20, IG20-SV2, MADD and DENN-SV are expressed in human tissues
To understand the physiological relevance of IG20 variants, we tested their expression patterns in human tissues. We used mRNA from 57 different human tissues and 14 different human cell lines in RT-PCR using multiple sets of IG20-specific primers. Four different primer pairs were designed to amplify regions of IG20 that contain alternatively spliced exons 13L, 16, 21, 26 and 34. Figure 2 shows expression patterns of IG20 variants in normal, benign and malignant forms of 10 different human tissue types. To validate RT-PCR results and to identify specific splice variants, we used mRNAs from several samples of the same tissue type in RT-PCR and obtained consistent results; but only one representative sample for each tissue type is shown. Our results further demonstrated that of the 36 exons, only a select few undergo alternative splicing. Together, the above data show that up to four different IG20 splice Figure 1 Human IG20 splice variants generated by alternative mRNA splicing. The cDNA sequence homology among the seven IG20 splice variants is shown. Solid bars represent regions of complete homology between all variants. Empty areas indicate exons 13L, 16, 21, 26 and 34, which, when spliced in different combinations, produce the seven splice variants shown on the left. Splicing of exon 34 in KIAA0358 and IG20-SV4 induces an early stop codon in exon 35. Shown also are different 5 0 untranslated regions (UTRs) for different splice variants Figure 2 RT-PCR of mRNA from human tissues using IG20 primers. A total of 57 samples representing normal, benign and malignant forms from 10 different human tissue types were used to extract mRNA and perform RT-PCR. This was accomplished using exon-specific primers, as described in Materials and methods. Several samples from the same tissue type were used; however, only one representative of these samples is presented in this figure. The splicing patterns of exons 13L, 16, 21, 26 and 34 for each of the tissues tested are shown variants are expressed in different patterns and levels in all human tissues tested, which extends limited earlier studies from us and others (Chow et al., 1996; Al-Zoubi and Efimova et al., 2001) .
Our analyses clearly indicated that none of the tissues tested expressed three of the splice variants namely, KIAA0358, IG20-FL and IG20-SV4. KIAA0358 was identified as an EST and was isolated from a human brain library, whereas IG20-SV4 was isolated as a partial clone from a human insulinoma library. Similarly, expression of the full-length clone that contains all 36 exons has not been detected. Further studies are required to establish whether they are naturally expressed in any other human tissues. Because of our inability to show their expression, these clones were not further investigated in this study.
All four IG20, MADD, IG20-SV2 and DENN-SV can encode proteins
We transfected 293T cells with cDNAs encoding each of the four splice variants of IG20 expressed in human tissues. Figure 3 shows levels of IG20 cDNAs amplified from mRNA transcripts that correspond to the transfected IG20 splice variant. Proteins encoded by these cDNAs were immunoprecipitated using anti-IG20 polyclonal antibodies and subjected to Western blotting using an anti-His monoclonal antibody. His-tagged IG20 protein variants encoded by the transfected cDNAs were seen at the expected molecular weight of about 215 kDa (Figure 4 ). Owing to small differences in their coding sequences, these proteins have similar apparent molecular weights. These results showed that the transfected cDNAs could encode the corresponding proteins.
We then assessed susceptibility of HeLa cells transfected with each of the above-described four IG20 splice variants to TNFa-and cyclohexamide (CHX)-induced apoptosis by trypan blue exclusion, chromatin condensation, and mitochondrial depolarization. Consistent with our previously published results (Al-Zoubi and Efimova et al., 2001) , HeLa-IG20 and HeLa-DENN-SV cells showed an increase and a decrease in TNFa-induced cell death, respectively, whereas HeLa-MADD cells showed no significant difference in apoptosis relative to the controls. Interestingly, HeLa-IG20-SV2 cells showed a phenotype similar to that of HeLa-MADD and HeLa-control cells (i.e., no significant effects on apoptosis) (data not shown).
Dominant-negative I-kappaB-alpha abrogates DENN-SV-mediated resistance to TNFa-induced apoptosis
In a previous report, we showed that IG20 enhances TNFa-induced apoptosis by activation of caspases 8 and 3 (Al-Zoubi and Efimova et al., 2001) . In this study, we carried out studies to begin to understand the mechanism by which DENN-SV confers resistance to TNFainduced apoptosis. We used CrmA and dominantnegative I-kappaB-alpha (DN-IkBa) that can block activation of caspases or NFkB, respectively. Our results ( Figure 5 ) showed that there was maximal inhibition of TNFa-induced apoptosis by CrmA in HeLa-IG20 cells relative to control cells, with little or no effect on HeLa-DENN-SV cells. In contrast, DN-IkBa significantly enhanced apoptosis in HeLa-DENN-SV cells and had minimal effects on HeLa-IG20 cells. Together, these results suggested that IG20 and DENN-SV play distinct roles in TNFa-induced signaling by activating either caspases that can be blocked by CrmA or NFkB that can be blocked by DN-IkBa, respectively. Figure 3 Relative intensities of cDNAs corresponding to IG20 splice variants in transfected cells. mRNAs from 293T cells stably transfected with IG20, MADD, IG20-SV2 and DENN-SV variants were extracted and 100 ng of each sample was used for RT-PCR as described in Materials and methods. RT-PCR products were subjected to PAGE using a 5% gel and stained with ethidium bromide. (a) Quantitation of band intensities was performed using ImageQuant analysis. Intensities were calculated as the percent intensity of the band corresponding to a specific IG20 variant to the total intensities of all bands within the same sample. Shown are means and standard deviations from three independent groups of cells transfected separately. P-values were o0.05 for all test groups. (b) PAGE photos for one of the transfections used to generate data shown in (a) Figure 4 Expression of 6-Histidine-tagged IG20 splice variants. The figure shows the expression of the four transfected IG20 cDNA constructs fused to a sequence encoding the 6-Histidine tag at the 5 0 end. The tagged proteins, seen at about 215 kDa, as expected, correspond to the transfected cDNAs of IG20 splice variants, indicating that the proteins were encoded by the transfected cDNAs Endogenous expression of IG20 splice variants correlates with susceptibility to TNFa-induced apoptosis To see whether expression of endogenous IG20 and DENN-SV were associated with increased and reduced cell death, respectively, we separated cells that were susceptible (Annexin V-positive) from those that were resistant (Annexin V-negative) to TNFa-induced apoptosis, and compared the levels of expression of IG20 variants. Our results (Figure 6a) showed that, relative to unseparated control HeLa cells, there was very little expression, if any, of IG20 (pro-apoptotic variant) and a much higher level of expression of DENN-SV (antiapoptotic variant) in resistant cells. In contrast, cells undergoing apoptosis showed a very high level of expression of IG20 and undetectable levels of other variants. We then measured the percentages of cells with depolarized mitochondria in these two subpopulations of cells, as another marker of apoptosis. As shown in Figure 6b , maximum apoptosis (cells with depolarized mitochondria) (93%) was noted in Annexin V-positive cells, whereas minimum apoptosis (8%) was seen in Annexin V-negative cells, compared to unseparated control cells (35%).
IG20 and DENN-SV exert contrasting effects on cell proliferation and responses to apoptosis-inducing agents
Our results demonstrated that HeLa-IG20 and HeLa-DENN-SV cells showed profound differences in their response to vinblastine treatment (Figure 7a and b). HeLa-DENN-SV cells were not significantly affected when they were treated with a dose of 0.05 mM. In contrast, there were only a few HeLa-IG20 colonies detectable indicating their enhanced susceptibility ( Figure 7a ). HeLa-control cells showed an intermediary response. Additionally, vinblastine-induced apoptosis was noted in 70 and 21% of HeLa-IG20 and Figure 6 Endogenous expression of IG20 variants and susceptibility to TNFa-induced apoptosis. (a) Magnetic separation of apoptotic and TNFa-resistant cells. Apoptotic cells were magnetized and physically separated from TNFa -resistant cells using the Annexin V-conjugated microbeads, as described in Materials and methods. mRNAs were then isolated from apoptotic and TNFaresistant cells separately and were used in RT-PCR using IG20-specific primers F-1 and B-1. The figure shows very little expression, if any, of IG20 (the proapoptotic variant) in cells resistant to TNFa-induced apoptosis, compared to control cells. In contrast, marked increase in expression of IG20 with no expression of DENN-SV (the antiapoptotic variant) is seen in apoptotic cells. (b) TNFa-induced mitochondrial depolarization in apoptotic and TNFa-resistant cells. Cells in (a) were then assessed for mitochondrial depolarization. As shown in the figure, maximal differences were seen in separated cells vs un-separated control cells. Bars represent averages from three wells for each group. The experiment was repeated at least three times and consistent results were obtained. These results were statistically significant, as P-values were o0.05 for both the resistant and apoptotic groups relative to controls HeLa-DENN-SV cells, respectively, compared with 46% of HeLa-controls, as measured by chromatin condensation ( Figure 7b) .
Next, the response of these cells to treatment with different doses of etoposide was evaluated. On average, HeLa-IG20 cells formed eight colonies after treatment with 5 mM etoposide. In contrast, HeLa-DENN-SV cells formed as many as 125 colonies, compared to 39 colonies formed by HeLa-control cells (Figure 8a and b). Upon treatment with 20 mM of etoposide, we found that HeLa-IG20 cells formed very few or no colonies, whereas HeLa-DENN-SV cells formed approximately 40 colonies. In addition, as shown in Figure 8a HeLa-DENN-SV cells were able to grow even after treatment with 30 mM of etoposide. These results were further substantiated by assessing apoptosis ( Figure 8c ) and cell division ( Figure 8d ) after etoposide treatment. Expectedly, HeLa-DENN-SV cells displayed a noticeable resistance to etoposide-induced apoptosis. However, interesting results were obtained with HeLa-IG20 cells, where they did not show a marked increase in susceptibility to apoptosis (Figure 8c ), but showed a Three different experiments using the indicated doses of etoposide were used to determine the effects of the drug on HeLacontrol, HeLa-IG20 and HeLa-DENN-SV cells. P-values were o0.05 for all test groups. (c) Etoposide-induced apoptosis. Cells treated with the indicated doses of etoposide were stained with Hoechst as described in Materials and methods and evaluated for chromatin condensation under a microscope. P-values were o0.05 for all test groups. (d) Cell division after etoposide treatment. Cells were stained with CFDA and then subjected to 5 mM etoposide treatment for 5 days. Cells were then harvested and evaluated by FACS for CFDA staining intensity. Histograms show relative levels of CFDA dye retention. The peak on the left within each histogram represents cells that have undergone cell division, and therefore, partially lost CFDA staining, whereas the peak on the right represents undivided cells that retained maximum CFDA staining Effects of IG20 isoforms on tumor cell survival and death EV Efimova et al significant decrease (9%) in cell division as indicated by CFDA staining, compared to DENN-SV (36%) and control (24%) cells ( Figure 8d ). Next, we evaluated the growth rates of HeLa-IG20 and HeLa-DENN-SV cells. Our data indicated that HeLa-IG20 and HeLa-DENN-SV cells showed growth attenuation or rapid growth, respectively, compared to HeLa-control cells (Figure 9a ). To evaluate their ability to grow in soft agar resulting in colony formation, we plated cells at different densities. On average, HeLa-DENN-SV cells and HeLa-IG20 cells formed 20 and two colonies, respectively, while HeLa-control cells formed four colonies (Figures 9b and c) . Additionally, HeLa-DENN-SV colonies were bigger, while HeLa-IG20 colonies were smaller, than HeLa-control colonies.
Effects of IG20 overexpression on cells that do not express endogenous IG20
Results in Figure 6 showed a clear correlation between the endogenous expression of IG20 and apoptosis. In the following experiment, we wanted to study the effects of expression of IG20 variant on cells that do not naturally express it. Therefore, we used PA-1, a human ovarian carcinoma cell line that expresses DENN-SV and MADD but not IG20 splice variant (Figure 10 ).
Our results showed that IG20 caused PA-1 cells to grow at a rate 10 times slower than untransfected PA-1 cells (Figure 11a ). Additionally, we found that IG20 renders PA-1 cells more susceptible to TNFa-induced apoptosis (Figure 11b ). Interestingly, more profound differences were seen with TRAIL (tumor necrosis factor-related apoptosis inducing ligand) treatment. PA-1 cells were almost completely resistant, while PA-1-IG20 cells were highly susceptible to TRAIL-induced apoptosis (Figure 11c ). Interestingly, transfecting PA-1 cells with IG20 led to a 10-fold increase in spontaneous apoptosis over cells transfected with a control plasmid (10 vs 0.98%). Similarly, IG20 rendered PA-1 cells more susceptible to treatment with g-radiation in combination with TRAIL ( Figure 11d ).
Since IG20 not only enhanced cell death induced by different agents, but also suppressed cell proliferation, we wondered whether it was affecting cell survival signaling pathway. Therefore, we assessed the effects of IG20 on NFkB activation upon TNFa treatment. Our results (Figure 11e ) clearly showed that IG20 suppressed TNFa-induced activation of NFkB, compared to control cells. (Zhang et al., 1998) and guanine nucleotide exchange (Brown and Howe, 1998; Iwasaki and Toyonaga, 2000) . Not until recently has it become apparent that this gene can encode several splice variants that arise from alternative mRNA splicing (AlZoubi and Efimova et al., 2001) . This raised the possibility that various functions assigned to this gene could result from selective expression of one or more splice variants in a given tissue, with potentially distinct functions.
Previous studies by Chow et al. (1998) . demonstrated that the human gene encoding DENN is located on chromosome 11p11 and consists of 16 exons, and indicated the potential for alternative splicing. In a more recent report, we extended these observations and identified additional splice variants, and confirmed that IG20 is located on chromosome 11p11, and showed that it consists of 36 exons (Al-Zoubi and Efimova et al., 2001) and not 16. In addition to the five splice variants that correspond to IG20, IG20-SV2, MADD, KIAA0358 and DENN-SV, previously reported by different laboratories including ours, we isolated two additional putative splice variants in the current study, designated IG20-FL and IG20-SV4. The differences between all seven IG20 variants are limited to alternative splicing of exons 13L, 16, 21, 26 and 34, that would follow mRNA splicing rules (Breitbart et al., 1987) . Exon 13L has an internal splice site, and splicing at that site deletes 129 nucleotides (2448-2576) resulting in 13S. Figure 1 illustrates deletion of specific exons and the resultant splice variants.
As shown in Figure 2 , only IG20, MADD, IG20-SV2 and DENN-SV, and not KIAA0358, IG20-SV4 and IG20-FL, are expressed in human tissues and could be of physiological relevance. These observations, however, do not preclude the possibility that IG20-FL, KIAA0358 and IG20-SV4 are expressed in other tissues not included in this study, or are transiently expressed.
The four variants expressed in human tissues arise from deletion of exons 21 and 26 (with the exception of a malignant pancreas) along with deletion of either exon 13L or 16, or both. The physiological relevance of exon 26 expression in malignant pancreas is not currently understood and needs further investigation.
Of particular interest are earlier findings that IG20 gene is highly expressed in tumor tissues (Chow and Lee, Figure 10 Expression of IG20 in HeLa and PA-1 cells. RT-PCR products using mature poly A þ mRNA extracted from HeLa and PA-1 cell lines are shown. IG20 F-1 and B-1 primers that flank exons 13L and 16 were used as described in Materials and methods. The figure demonstrates that cDNA bands that correspond to the four IG20 splice variants (i.e., IG20, MADD, IG20-SV2 and DENN-SV) are expressed in HeLa cells, whereas only MADD and DENN-SV are expressed in PA-1 cells Figure 11 Effects of IG20 on PA-1 cell phenotypes. (a) Growth rates. PA-1 and PA-1-IG20 cells were plated as described in Materials and methods. Cells were then harvested and counted on the indicated days. Data are presented as mean7s.d. of three plates for each sample. P-values were o0.05 for all test groups. (b) TNFainduced apoptosis. Cells were either untreated or treated with TNFa and CHX for 3 h, as described in Materials and methods and then tested for percentages of cells with active caspase 3. (c) TRAILinduced apoptosis. Cells were either untreated or treated with TRAIL for 3 h and then tested for percentages of cells with active caspase 3, in the presence or absence of z-VAD, an inhibitor of caspase activation. (d) Response to g-radiation and TRAIL treatment. PA-1-IG20 cells exposed to 6 and 12 Gy of g-radiation were plated as described in Materials and methods. After 24 h, cells were either untreated or treated with TRAIL for 3 h. All cells were then harvested and tested for levels of active caspase 3. (e) TNFa and TRAIL-induced NFkB activation. Cells transfected with the NFkB-luciferase reporter were serum-deprived and then subjected to mock, TNFa, TRAIL or z-VAD treatments for 5 h. Cells were then lysed and tested for levels of luciferase activity. Activity is presented as the levels of luciferase activity under treatment over the levels of activity under no treatment 1996; Murakami-Mori et al., 1999; Al-Zoubi and Efimova et al., 2001), particularly neuroendocrine tumors (Goto et al., 1992; Cunningham, 1996) . However, at that time the splice variants had not yet been fully delineated and thus one could not attribute higher expression to a particular variant. Our current findings showed that DENN-SV is constitutively expressed in all tissues; and relative to other variants, it is expressed at higher levels in tumors. A very interesting recent study by Lim and Chow (2002) showed that cancer cells expressed 25-50-fold excess of DENN relative to normal controls. Treating these cells with DENN-targeted antisense oligodeoxinucleotides resulted in the abrogation of DENN expression, accompanied by increased cell death and reduced cell proliferation. In this study, since expression of different splice variants in the cells was not evaluated, it is not entirely clear whether the resulting effects might have been due to silencing of all expressed splice variants rather than just the DENN splice variant. Nevertheless, these studies show that IG20 gene plays an important role in cell survival and death.
The function of a given IG20 splice variant cannot be readily assessed due to the expression of more than one variant within a given cell. Although we have already generated three different antipeptide antibodies, we could not use them to distinguish between different variants due to relatively small differences between different variants (Al-Zoubi and Efimova et al., 2001). Therefore, we generated HeLa cells permanently transfected with each of the four IG20 variants and showed the overexpression of each of the four variants using a one-step internally controlled RT-PCR that simultaneously compares expression levels of all the four IG20 variants. Additionally, we showed expression of the corresponding proteins using anti His antibodies.
As expected, cells transfected with IG20 and DENN-SV were most susceptible and resistant to TNFa-induced apoptosis, respectively; whereas cells transfected with MADD or IG20-SV2 did not show significant differences relative to cells transfected with a control plasmid (data not shown). Since DENN-SV lacks both exons 13L and 16, MADD lacks exon 16 and IG20-SV2 lacks exon 13L, these results demonstrated that expression of both exons 13L and 16, as seen in IG20, is required for antiproliferative and proapoptotic properties, whereas deletion of both exons, as seen in DENN-SV, is required for proproliferative and antiapoptotic properties.
To test for potential correlation between the expression of endogenous IG20 variants and susceptibility of cells to TNFa-induced apoptosis, we evaluated their expression in unseparated HeLa-control cells, and cells that were resistant or susceptible to apoptosis induced by TNFa and CHX. Interestingly, our data showed a clear correlation between the expression of IG20 and the ability of cells to undergo apoptosis on one hand, and expression of DENN-SV and the ability to resist apoptosis on the other. Differences in the expression of different variants were not due to indirect inhibitory effects of protein synthesis by CHX, since there was no significant difference between cells that were either untreated or treated with CHX alone (not shown). Another important implication of these results is that they provide a possible explanation as to why we do not see maximal proapoptotic or antiapoptotic effects in a heterogeneous HeLa cell population that is transfected with IG20 or DENN-SV, respectively. We speculate that this could also be due to mutual regulation of the function of IG20 and DENN-SV that are naturally coexpressed, albeit, at different levels in HeLa cells.
Some earlier studies have shown that IG20 is differentially expressed in tumor cells, while others have shown that IG20 can play an important role in cell death (Schievella et al., 1997; Murakami-Mori et al., 1999; AlZoubi and Efimova et al., 2001; Lim and Chow, 2002; Smrcka et al., 2003) . In the current study, we evaluated the effects of IG20 and DENN-SV on the apoptotic response to common cancer treatments. HeLa-IG20 and HeLa-DENN-SV cells were more susceptible and resistant, respectively, to vinblastine and TNFa treatment. However, surprisingly, HeLa-IG20 cells and HeLa-control cells showed a similar response to etoposide-induced apoptosis and yet had a fewer number of cells at the end of the observation period. This suggested that etoposide treatment might have suppressed the ability of HeLa-IG20 cells to proliferate. Cell proliferation data showed that HeLa-IG20 cells had reduced growth, compared to HeLa-control cells. Together, these results suggest that the apparent resistance of HeLa-DENN-SV cells to etoposide treatment is due to a combination of enhanced resistance to apoptosis and increased cell division, whereas the sensitivity of HeLa-IG20 is mainly due to a decreased rate of cell division.
When we further investigated the effects of IG20 and DENN-SV on cell proliferation, HeLa-DENN-SV and HeLa-IG20 showed greater and reduced proliferation, respectively, relative to control cells. We also show a difference in the anchorage-independent growth of both HeLa-DENN-SV and HeLa-IG20 cells compared to HeLa-control. DENN-SV cells formed higher numbers of larger colonies in soft agar indicating enhanced anchorage-independent growth. In contrast, HeLa-IG20 cells showed reduced growth and formed smaller as well as fewer numbers of colonies in soft agar. These results provided further evidence of the contrasting effects of IG20 and DENN-SV on proliferation and cell survival.
Next, we tested the effects of expressing IG20 variant in PA-1 human ovarian carcinoma cell line that do not naturally express it. Relative to PA-1 cells, PA-1-IG20 cells showed significantly reduced proliferation and were much more susceptible to spontaneous, TNFa-and TRAIL-induced apoptosis. These cells were even more susceptible to a combined treatment with TRAIL and gradiation. This is not entirely surprising, because TRAIL-induced signaling leading to apoptosis is similar to that induced by TNFa, and requires recruitment of FADD and caspase 8 to the death inducing signaling complex (DISC). Of interest is the finding that TRAIL, a member of the TNF superfamily, can induce apoptosis in some tumor cells but not in others (Wajant et al., 2002) . This raises the possibility that IG20 could be used to render cells that are otherwise resistant to become susceptible (as seen with PA-1 cells) to TRAILinduced cell death, and could have significant implications for cancer therapy. It is interesting to note that percentages of cells with active caspases were somewhat less in PA-1 cells treated with 12 Gy þ TRAIL relative to those treated with lesser doses (six or eight Gy þ TRAIL). At this time, we do not know the reason for this apparent effect. However, we speculate that it might be related to differences in cell cycle progression/ arrest induced by different doses of g-radiation. Further studies are needed to understand fully the reasons for this apparent effect.
Different TNFR1-mediated signaling pathways can be activated through the selective recruitment of adaptor proteins to the TNFR1/TRADD complex (Hsu et al., 1996a; Varfolomeev et al., 1996) . Recruitment of FADD leads to the activation of cell death pathway through caspase 8 activation (Chinnaiyan et al., 1996) . On the other hand, recruitment of RIP/TRAF2 can lead to the activation of cell survival pathway through NFkB activation (Rothe et al., 1995; Hsu et al., 1996b; Ting et al., 1996) . NFkB plays an important role in cell proliferation, cell cycle progression and in inhibition of apoptosis (Liu et al., 1996; Malinin et al., 1997; Regnier et al., 1997; Woronicz et al., 1997; Kelliher et al., 1998) . It has been shown that abrogation of the function of NFkB renders cells more susceptible to TNFa-induced apoptosis (Brockman et al., 1995; Beg and Baltimore 1996) . In these studies, an DN-IkBa, was shown to augment apoptosis.
What determines the engagement of either FADD or RIP/TRAF2 is not well understood. However, our previous results showed that IG20 may play an important role in this process. Both IG20 and DENN-SV can interact with TNFR1; however, enhanced activation of caspases was seen only in cells transfected with IG20 that could be inhibited by CrmA (Al-Zoubi and Efimova et al., 2001 ). In the current study, we present data that suggest that DN-IkBa could inhibit increased resistance to TNFa-induced apoptosis seen in HeLa-DENN-SV cells. Together, these results suggest that IG20 and DENN-SV, which can directly interact with TNFR1, might act as molecular switches and determine the nature of cellular responses to TNFa treatment. The putative mechanisms by which these variants can affect TNFa-induced signaling are not currently understood and need further investigation. However, since DENN-SV is constitutively expressed and is recruited to the TNFR1/TRADD complex, it might confer its proproliferative/antiapoptotic effects by activating NFkB pathway. If IG20 is expressed, it likely will be preferentially recruited to the TNFR1/TRADD complex leading to activation of caspase 8 and confer its proapoptotic effects. IG20 expression appears to override DENN-SV effects. This is consistent with the known effects of caspase 8, which can not only trigger apoptosis but also suppress the cell survival pathway by either cleaving RIP or IkBa and prevent NFkB activation Martinon et al., 2000) . Together, these results represent the first insight into the potential mechanisms by which IG20 and DENN-SV may differentially regulate cell death and survival.
The default function of IG20 gene, most likely, is to aid in cell survival and is mediated through constitutive expression of DENN-SV in all cells. However, when a cell has to cease replicating and/or undergo apoptosis, then it might allow expression of IG20, which functions primarily as an antiproliferative and proapoptotic factor. IG20 appears to exert its effects through activation of caspases and/or suppression of NFkB activation as seen in PA-1 cells.
In conclusion, results presented in this study provide a comprehensive analysis of alternative splicing of IG20 gene and its differential expression in human normal and tumor tissues. We provide clear evidence to suggest that IG20 and DENN-SV have contrasting effects on apoptosis and cell proliferation. However, more detailed studies are required to understand fully the molecular mechanisms that regulate expression of IG20 splice variants and their action.
Materials and methods
RT-PCR using RNA from human tissues
Human tissue samples were provided by the Cooperative Human Tissue Network (CHTN), which is funded by the National Cancer Institute. Highly pure intact full-length poly-A þ mRNAs were directly isolated from various tissues using mMACS mRNA Isolation Kit (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's protocol. Briefly, tissues were minced, lysed, mixed with the MicroBeads conjugated to Oligo (dT) and then loaded onto the mMACS magnetic columns. The columns were washed and the bound mRNAs eluted with hot (651C) RNase-free water. mRNA (50 ng) from each sample was used in SuperScript-One-Step RT-PCR System (Life Technologies, Rockville, MD, USA). Depending on the length of the product, RT-PCR protocols differed only in the extension time (at 721C) and the primers used; otherwise, protocols were identical. A first incubation at 501C for 30 min was followed by incubation at 941C for 2 min. Subsequent 30 cycles of PCR were carried out at 941C for 30 s, 551C for 30 s and 721C for variable time periods (as described below), followed by a final incubation at 721C for 7 min. For amplifying exons 13L and 16, F-1 and B-1 primer pair (5 0 CGG GAC TCT GAC TCC GAA CCT AC 3 0 and 5 0 GCG GTT CAG CTT GCT CAG GAC 3 0 , respectively) was used, with 1 min extension time. For amplifying exon 21, F3453 and B3648 primer pair (5 0 AAG TGC CAC AGG AAA GGG TC 3 0 and 5 0 TGC GCT GAT CTG GGA CTT TT 3 0 , respectively) was used, with 30 s extension time. For amplifying exon 26, F3944 and B4123 primer pair (5 0 AGC CAT GCA TAA AGG AGA AG 3 0 and 5 0 GGT CCC ATA AAG TAG AAC GC 3 0 , respectively) was used, with 30 s extension time. For amplifying exon 34, F4824 and B5092 primer pair (5 0 CTG CAG GTG ACC CTG GAA GGG ATC 3 0 and 5 0 TGT ACC CGG GTC AGC TAG AGA CAG GCC 3 0 , respectively) was used, with 30 s extension time. All primers were used at 10 mM each. The resultant cDNAs were separated on 5% polyacrylamide gels (PAGE) and compared to molecular size markers to determine the product size.
Sequencing of RT-PCR products
To sequence the PCR products, 10 ml of cDNA from representative RT--PCR products were run on PAGE until the desired fragments were clearly separated. Then, bands corresponding to the expected size of a given variant were excised, purified and cloned into pGEM-Teasy vector (Promega, Madison, WI, USA), and used to transform E. coli DH5a. Clones containing the desired fragments were identified by restriction analysis and sequenced using the corresponding primers described above.
Cloning of IG20 splice variants into mammalian expression vectors IG20, MADD and DENN-SV were each separately cloned into the multiple cloning sites (MCS) of pBKRSV (Stratagene, La Jolla, CA, USA), and pCDNA 3.1 His vector (Invitrogen, Carlsbad, CA, USA) as previously described (Al-Zoubi and Efimova et al., 2001) . The remaining four IG20 splice variants (i.e., IG20-FL, KIAA0358, IG20-SV2 and IG20-SV4) were first cloned into pBKRSV and then into pCDNA 3.1 His vector. We used IG20 cloned into pBKRSV as a backbone, as described below. KIAA0358 (clone number hh00017 inserted at the SalI-NotI site of the pBluescript IISK þ (pBSSK) vector) was kindly provided by Kazusa DNA Research Institute (Chiba, Japan). Similarly, IG20-SV4 was cloned into pBSSKII at the SalI-NotI site. Both KIAA0358 and IG20-SV4 were excised out of pBSSKII and cloned into pBKRSV at the SalI and NotI sites. To clone IG20-FL into pBKRSV, both pBSSK-KIAA0358 and pBKRSV-IG20 were digested with AatII and KpnI that flank the region containing exons 21 and 26 (as shown in Figure 1 ). The AatII-KpnI fragment of KIAA0358 that contains unspliced exons 21 and 26 was used to replace the corresponding fragment in pBKRSV-IG20 that lacks these exons. To clone IG20-SV2 into pBKRSV, both DENN-SV and pBKRSV-IG20 were digested with AatII, which cuts at two sites on IG20 (and DENN-SV) that flank exons 13L and 16. Digestion of pBKRSV-IG20 with AatII produced two fragments of about 1 and 8.3 kb, and digestion of DENN-SV produced two fragments of about 1 and 5 kb. The 1 kb fragments from both were further digested with Esp31 that cuts between exons 13L and 16. The AatII-Esp31 fragment from DENN-SV that spans exon 13L (where exon 13L is spliced into 13S) was used to replace the corresponding fragment in pBKRSV-IG20 (where exon 13L is unspliced). Restriction analyses and sequencing confirmed the appropriate cloning of each of the above cDNAs into pBKRSV. To construct tagged cDNAs, we used pCDNA 3.1 His-IG20 as a backbone. IG20-FL, IG20-SV2, IG20-SV4 and KIAA0358 were cloned into pCDNA 3.1 His-IG20 at ClaI site at 279 nucleotides downstream of IG20 ATG start codon and NotI site at the C-terminal of IG20. The correct clones were identified by restriction analyses using NotI and ClaI, and then with AatII, and by sequencing.
Transfection of mammalian cells with cDNAs encoding different IG20 splice variants
Control pCDNA 3.1 His vector, or vector containing various cDNAs, were used for transfecting HeLa, 293T and PA-1 cell lines. Cells were transfected using Super-Fect Transfection Reagent (Qiagen) according to previously published protocols (Al-Zoubi and Efimova et al., 2001) . To select for permanently transfected cells, growth medium was replaced at 24 h posttransfection, and then once every 3 days for 21 days, with fresh medium containing 400 mg/ml G418. Expression of transfected cDNAs was then confirmed by immunoblotting as described below.
Immunoprecipitation of IG20 splice variants
Permanently transfected human embryonic kidney (293T) cells were plated in 150 cm 2 dishes at 8 Â 10 6 cells/dish and grown overnight. Next day, cells were harvested by trypsinization and then counted; equal numbers of cells from all samples were used. Further processing of cells and cell lysates was carried out at 41C. Cells were washed once in ice-cold PBS and were incubated in lysis buffer T (20 mM Tris-Cl, pH 7.5, 1% Triton X-100, 137 mM NaCl, 25 mM b-glycerophosphate, 2 mM EDTA, 1 mM Na 3 VO 4 , 2 mM sodium pyrophosphate, 10% (v/v) glycerol, 10 mg/ml leupeptin and 2 mM phenylmethylsulfonyl fluoride) for 1 h. Lysates were subjected to centrifugation at 13 000 r.p.m. for 30 min, supernatants were transferred to other tubes and total protein concentration was determined. Equal amounts of total protein from each sample were used in subsequent immunoprecipitations. Samples were precleared by incubation with 5 ml/sample of normal rabbit sera for 30 min followed by addition of 25 ml protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and further incubation for 30 min. Samples were then centrifuged at 13000 r.p.m. for 1 min, and the supernatants were transferred into new tubes and incubated at 41C overnight with 5 ml of a mixture of anti-IG20 N, C and M antibodies. These antibodies were generated against three different peptides derived from the N-terminus (N) C-terminus (C) and the middle part (M) of the protein as described previously (AlZoubi and Efimova et al., 2001) . To detect specific IG20 variants, the above immunoprecipitated samples were separated and then transferred onto nitrocellulose membrane and detected using anti-His monoclonal antibodies (Clonetech).
TNFa treatment of cells
Cells were plated in six-well plates at 1.2 Â 10 5 in growth medium. After 24 h, cells were either untreated or treated with 10 ng/ml TNF-a and 10 mg/ml CHX for 6 h. To assess the effects of TNFa and CHX treatment, cells were either stained with 100 nM tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes, Eugene, OR, USA) for 10 min, harvested by trypsinization, washed once with ice-cold PBS and then subjected to FACS analysis, or were stained with either trypan blue and evaluated for viability using a light microscope, or with 1 mg/ml Hoechst 33342 (Sigma) for 10 min and evaluated for chromatin condensation in situ using a Diaphot 200 inverted microscope with an epi-fluorescence attachment (Nikon, Melville, NY, USA).
Drug treatment of cells
Cells were plated (10 5 cells/well) the day before treatment into six-well plates. Cells were treated with etoposide for 24 h or vinblastine for 1 h at indicated concentrations. After treatment, cells were washed three times with PBS and then replenished with fresh media and incubated at 371C. After 2 weeks, cells were fixed in ice-cold methanol and stained with crystal violet for visualization.
TRAIL treatment of cells
PA-1 cells were plated in six-well dishes (5 Â 10 5 cells/well). Next day, cells were treated in situ with 50 ng/ml TRAIL (Peprotech, Rocky Hill, NJ, USA) for 3 h with or without 50 mM z-VAD (30 min preincubation). Cells were then assayed for levels of active caspase 3.
Active caspase 3 assay
Cells were harvested, washed once with PBS and then fixed in Cytofix/Cytoperm solution and washed with Perm/Wash buffer as suggested by the manufacturer (Pharmingen, San Diego, CA, USA). Cells were then stained with PE-conjugated rabbit anti-active caspase 3 antibody according to the manufacturer's protocol (Pharmingen). Cells were then subjected to FACS analysis to determine percentage of cells with active caspase 3.
Proliferation and colony formation in soft agar
To measure cell proliferation, cells were plated in triplicates at 1 Â 10 5 cells/100 mm 2 plate, and then were harvested and counted on days 1, 3 and 5 after plating. To assess the ability of cells to form colonies in soft agar, 1.4% agarose in water was mixed with 2 Â DMEM (20% FCS, 2 Â pen/strep) to create the bottom layer; 1 ml of this was used to line the bottom of each well (six-well dishes). Variable numbers of cells diluted in 1 ml of DMEM (supplemented with 10% FCS, pen/ strep) were mixed with 1 ml of 0.7% agarose in DMEM (liquid form) and used to form the top layer (final 0.35% agarose in DMEM 10% FCS, penicillin/streptomycin). Colony formation was observed under a microscope.
CFDA staining of cells
A measure of 1 Â 10 5 cells/100 mm 2 plate was stained with 2 mM CFDA (Molecular Probes, Eugene, OR, USA) in situ in 5 ml PBS/100 mm 2 for 10 min at 371C. Cells were then washed three times and replenished with new media. Cells were harvested 5 days later and analysed by FACS.
Hoechst staining
Cells were stained in situ with 1 mg/ml of Hoechst 33342 (Sigma, St Louis, MO, USA) in DMEM for 10 min at 371C. Chromatin condensation was then visualized in situ using a Diaphot 200 inverted microscope with an epifluorescence attachment (Nikon, Inc., Melville, NY, USA). In all, 10 different fields were randomly chosen to determine the average number of cells with condensed chromatin (apoptotic) as compared to live cells.
Luciferase assay for NFkB activation
Measurement of NFkB activation was performed using the Dual-Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Briefly, cells were plated in 12-well dishes (5 Â 10 5 PA-1 cells/plate) and 18-24 h later were cotransfected with 0.01 mg/well of NFkB firefly luciferase reporter construct and 0.001 mg/well of Renilla luciferase control vector pRL-SV40. Cells were allowed to recover for 24 h and then replenished with serum-free medium. Next day, cells were left untreated or treated for 5 h with TNFa or TRAIL. Subsequently, they were washed and lysed in situ for 30 min with gentle agitation using the manufacturer's lysis buffer. A volume of 20 ml of each lysate was then used to test for levels of firefly luciferase activity and normalized with the levels of Renilla luciferase activity.
Transfection of cells with DN-IkBa and CrmA
Cells were plated in six-well plates at 1.5 Â 10 5 /well in growth media. After 24 h, cells were transfected with either a cDNA encoding farnesylated GFP (GFP-f) alone, or cotransfected with either an empty vector, or a vector containing cDNA encoding either CrmA or DN-IkBa, at a 1 : 5 ratio. At 24 h post-transfection, cells were either untreated or treated with TNFa and CHX for 6 h, as described above. Then, cells were stained with TMRE and subjected to FACS analysis; only GFP-f-gated cells were included in the analysis.
RT-PCR of TNFa-resistant HeLa cells
To separate cells that were undergoing apoptosis, or resistant to apoptosis upon TNFa treatment, we used the Annexin V microbeads (Miltenyi Biotec, Inc.) according to the manufacturer's protocol. Annexin V is a phospholipid-binding protein that recognizes phosphatidylserine on the surface of apoptotic cells. Briefly, cells were plated and treated with TNFa and CHX for 6 h as described above, washed once with PBS to remove dead cells and debri, collected, passed through 30 mM filter, and incubated with Annexin V microbeads for 15 min at 6-121C, and then washed once and resuspended in 500 ml buffer. Cells were then passed through a magnetic column. Flow through included nonapoptotic, TNFa-resistant cells, whereas cells bound to the column represented apoptotic cells. Columns were washed three times with buffer, removed from magnet and cells bound to the matrix were eluted. Untreated control, TNFa-resistant and apoptotic cells were then used for isolation of Poly-A þ mRNA using the mMACS mRNA Isolation Kit (Miltenyi Biotec), or were used for TMRE staining to determine percentage of apoptotic cells, as described above.
